Incyte Announces New Data from across its Oncology Portfolio to be Presented at ESMO Congress 2023
16 Outubro 2023 - 9:00AM
Business Wire
Incyte (Nasdaq:INCY) today announced that abstracts featuring
new data from its oncology portfolio will be presented at the
upcoming European Society for Medical Oncology (ESMO) Congress
2023, held October 20-24 in Madrid.
"We look forward to sharing data from our oncology portfolio
with the scientific community at this year’s ESMO Congress,” said
Steven Stein, M.D., Chief Medical Officer, Incyte. “Presentations,
including results from studies of retifanlimab and capmatinib,
focused on patients with endometrial cancer, Merkel cell carcinoma
and non-small cell lung cancer, showcase our continued efforts to
pursue innovative therapies for patients with cancer.”
Key abstracts from Incyte-sponsored and partner programs
include:
Poster Presentations
Immuno-oncology (IO)
Retifanlimab in Patients with Recurrent Microsatellite
Instability-High (MSI-H) or Deficient Mismatch Repair (dMMR)
Endometrial Cancer: Final Results from the POD1UM-101 Study (Cohort
H) (Abstract #755P. Topic: Gynecological Cancers. Sunday,
October 22, 6:00 a.m. – 7:00 a.m. ET)
Updated Results from POD1UM-201: A Phase 2 Study of
Retifanlimab in Patients with Advanced or Metastatic Merkel Cell
Carcinoma (MCC) (Abstract #1146P. Topic: Melanoma and Other
Skin Tumors. Sunday, October 22, 6:00 a.m. – 7:00 a.m. ET)
Capmatinib
Efficacy of Capmatinib Compared to Standard of Care for
German Patients with Locally Advanced or Metastatic NSCLC Harboring
METex14 Mutations: Results from the RECAP Study1 (Abstract
#1383P. Topic: NSCLC, Metastatic. Monday, October 23, 6:00 a.m. –
7:00 a.m. ET)
Capmatinib vs Docetaxel as Second- or Third-line (2/3L)
Therapy in Patients (Pts) with METex14-Mutated Advanced NSCLC
(aNSCLC): The GeoMETry-3 Trial1 (Abstract #1391P. Topic: NSCLC,
Metastatic. Monday, October 23, 6:00 a.m. – 7:00 a.m. ET)
For full session details and data presentation listings, please
see the ESMO Congress 2023
(https://www.esmo.org/meeting-calendar/esmo-congress-2023/programme)
online program.
About Zynyz™ (retifanlimab-dlwr)
Zynyz (retifanlimab-dlwr), is an intravenous PD-1 inhibitor
indicated in the U.S. for the treatment of adult patients with
metastatic or recurrent locally advanced Merkel cell carcinoma
(MCC). This indication is approved under accelerated approval based
on tumor response rate and duration of response. Continued approval
for this indication may be contingent upon verification and
description of clinical benefit in confirmatory trials.
Zynyz is marketed by Incyte in the U.S. In 2017, Incyte entered
into an exclusive collaboration and license agreement with
MacroGenics, Inc. for global rights to retifanlimab.
Zynyz is a trademark of Incyte.
About Tabrecta® (capmatinib)
Tabrecta is approved in several countries including the EU,
United States (U.S.), Japan and Switzerland. It is the number one
prescribed targeted therapy for patients with advanced non-small
cell lung cancer (NSCLC) with alterations leading to
mesenchymal-epithelial transition factor gene exon 14 (METex14)
skipping globally2.
Tabrecta is a kinase inhibitor that targets
mesenchymal-epithelial transition (MET). Tabrecta was discovered by
Incyte and licensed to Novartis in 2009. Under the agreement,
Incyte granted Novartis worldwide exclusive development and
commercialization rights to capmatinib and certain back-up
compounds in all indications.
About Incyte
Incyte is a Wilmington, Delaware-based, global biopharmaceutical
company focused on finding solutions for serious unmet medical
needs through the discovery, development and commercialization of
proprietary therapeutics. For additional information on Incyte,
please visit Incyte.com and follow @Incyte.
Forward-Looking Statements
Except for the historical information set forth herein, the
matters set forth in this press release, including statements
regarding the presentation of data from Incyte’s clinical
development pipeline, whether or when any development compounds or
combinations will be approved or commercially available for use in
humans anywhere in the world outside of the already approved
indications in specific regions and Incyte’s goal of improving the
lives of patients, contain predictions, estimates and other
forward-looking statements.
These forward-looking statements are based on Incyte’s current
expectations and subject to risks and uncertainties that may cause
actual results to differ materially, including unanticipated
developments in and risks related to: unanticipated delays; further
research and development and the results of clinical trials
possibly being unsuccessful or insufficient to meet applicable
regulatory standards or warrant continued development; the ability
to enroll sufficient numbers of subjects in clinical trials;
determinations made by the FDA, EMA, and other regulatory
authorities; the efficacy or safety of Incyte and its partners’
products; the acceptance of Incyte and its partners’ products in
the marketplace; market competition; sales, marketing,
manufacturing and distribution requirements; and other risks
detailed from time to time in Incyte’s reports filed with the
Securities and Exchange Commission, including its annual report and
its quarterly report on Form 10-Q for the quarter ended June 30,
2023. Incyte disclaims any intent or obligation to update these
forward-looking statements.
______________________________ 1
Novartis-sponsored abstract 2 Data on file
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231016304311/en/
Media media@incyte.com Investors ir@incyte.com
Incyte (NASDAQ:INCY)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Incyte (NASDAQ:INCY)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024